OTC Markets OTCPK - Delayed Quote USD

Eisai Co., Ltd. (ESAIY)

Compare
8.50 -0.14 (-1.62%)
As of 1:53 PM EDT. Market Open.

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Haruo Naito CEO, Representative Corporate Officer & Director -- -- 1947
Mr. Gary Hendler Senior VP & President of EMEA Region -- -- 1966
Dr. Lynn D. Kramer FAAN, M.D. VP & Chief Clinical Officer -- -- 1950
Ms. Yanhui Feng Senior Vice President -- -- 1972
Mitsuru Shomon VP & CFO -- -- --
Mr. Keisuke Naito Representative Corporate Officer, EVP, COO & Chief Growth Officer -- -- 1988
Makoto Hoketsu VP & Chief Information Officer -- -- --
Mr. Masatomi Akana Senior VP, Chief Government Relations Officer & Chief IR Officer -- -- 1967
Shin Kato VP, General Counsel & Chief Compliance Officer -- -- 1971
Ms. Sayoko Sasaki Vice President of Corporate Communications & Sustainability -- -- 1968

Eisai Co., Ltd.

4-6-10, Koishikawa
Bunkyo-ku
Tokyo, 112-8088
Japan
81 3 3817 3700 https://www.eisai.co.jp
Sector:?
Healthcare
Full Time Employees:?
11,067

Description

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Corporate Governance

Eisai Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 8, 2024 at 3:30 AM UTC

Eisai Co., Ltd. Earnings Date

Recent Events

March 27, 2024 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers